SEC Company Response from Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) (APVO) — Aug 31, 2026
Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)
Date: Aug. 31, 2026 · CIK: 0001671584 · Accession: 0001193125-26-377083
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-298483
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Ms. Jessica Dickerson Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed August 21, 2026 File No. 333-298483
Dear Ms. Jessica Dickerson:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-298483) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on September 2, 2026, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.
Very truly yours,
Aptevo Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
August 31, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Jessica Dickerson
Re: Aptevo Therapeutics Inc.
Registration Statement on Form S-1
Filed August 21, 2026
File No. 333-298483
Dear Ms. Jessica Dickerson:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-298483) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on September 2, 2026, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.
Very truly yours,
Aptevo Therapeutics Inc.
By: /s/ Jeffrey G. Lamothe
Jeffrey G. Lamothe
President and Chief Executive Officer
CC:
SoYoung Kwon, Aptevo Therapeutics Inc.
Daphne Taylor, Aptevo Therapeutics Inc.
Sean M. Donahue, Paul Hastings LLP